Led · Series A · Nov 2019

Ad-Lib offers a SaaS marketing technology platform that streamlines creative ad production workflows, automates digital asset creation, and optimises creative performance across display, video, social, native and mobile using AI. The platform is directly integrated with major channels including Facebook, YouTube, Instagram and Google Marketing Platform, and the company is a certified creative partner of Google and Facebook. Clients include large global brands such as Nestle, J&J and Virgin. The company employs about 80 staff across offices in London, Madrid, Dubai, Singapore, Tokyo, Sydney and Manila. Ad-Lib plans to use new funding to strengthen its technology platform, expand its senior leadership team, grow further in EMEA and APAC, and launch a US headquarters in New York. The business was founded in 2017 and is led by CEO Oli Marlow Thomas.

Participated · Equity · Jun 2012

Visual IQ is a Needham, MA-based provider of cross-channel marketing intelligence software led by co-founder and CEO Manu Mathew. Its hosted IQ Intelligence Suite reveals cross-channel performance insights hidden within companies’ marketing data. The suite provides marketers and agencies with actionable recommendations to improve marketing effectiveness. The company raised $12M in funding to support its growth. Visual IQ intends to use the capital to accelerate product innovation and sales growth. Visual IQ is a Needham, MA-based provider of software and services that support marketing investment decisions. Its SaaS analytics solutions give marketers and agencies performance insights across a complex and ever-expanding media mix to improve return on marketing investments. Clients include AT&T, CVS, Texas Instruments and Vanguard Financial. The company also partners with leading media and creative agencies and other marketing-technology companies to bring its solutions to their clients. Visual IQ completed a $3M growth funding from Fog City Capital and plans to use the capital to expand its team, advance partner relationships and improve its technology infrastructure. Founder and CEO Manu Mathew said Fog City Capital's domain expertise in digital marketing and analytics will help the company scale its growth.

Participated · Series B · Apr 2011

Cianna Medical develops and markets SAVI technologies for breast cancer treatment, including a brachytherapy applicator and the SAVI SCOUT surgical guidance system. SAVI SCOUT uses passive non-radioactive electromagnetic wave technology to provide real-time guidance and can be placed in tissue up to seven days before surgery. The company received FDA clearance for SAVI SCOUT in late 2014 and is currently launching the product. The SAVI brachytherapy applicator delivers individualized radiation therapy and can reduce treatment time to about five days. Cianna is using new financing to support commercialization and ramp up adoption of the SCOUT system. Cianna Medical manufactures the SAVI strut-based brachytherapy applicator, which delivers individualized partial breast radiation from inside the breast after lumpectomy. The SAVI system uses multiple catheters to direct dose customization that minimizes exposure to healthy tissue and reduces complications. The company reports that 20,000 women have been treated with the SAVI applicator to date. Cianna is focused on expanding commercialization of SAVI both in the U.S. and abroad while continuing product development. Management has stated the company will selectively invest in its new product pipeline as commercialization ramps. To support these efforts, Cianna recently secured external financing to strengthen its working capital position. Cianna Medical manufactures and markets the SAVI multicatheter breast brachytherapy applicator, a single-entry device that enables customized, patient-specific accelerated partial breast irradiation (APBI) delivered in a shortened five-day course. The company intends to use new funding to expand sales and marketing of SAVI in the U.S. and internationally and to develop new products synergistic to its radiation oncology and surgery focus. Management notes SAVI is increasingly adopted by clinicians and patients, and the company is experiencing double-digit growth following use at hundreds of leading breast cancer treatment facilities. Clinical studies from institutions such as MD Anderson and UC San Diego have supported broader eligibility and improved outcomes with SAVI, including less skin toxicity and improved cosmesis. The company is based in Aliso Viejo, California, and emphasizes making APBI available to more women who choose breast-conserving therapy. Cianna Medical is an Aliso Viejo-based company developing treatments for early-stage breast cancer. It is a spinout from BioLucent, Inc. On April 7, 2009 the firm announced completion of a Series B funding round worth more than $10M. The company said the new funding will be used to commercialize its technology. Investors named in the round include Emergent Medical Partners, Saints Capital, Mitsubishi International, Fog City Fund, and several private individuals. The raise brings Cianna Medical's total capital raised to $19M. Cianna Medical is an Aliso Viejo-based spinout of BioLucent developing breast brachytherapy technology. Its core product provides a shortened course of high-dose radiation therapy for treating early-stage breast cancer. The company said it will use new funding to further commercialize that technology. Cianna announced a $9M Series A funding round to support those commercialization efforts. Investors in the round include Fog City Fund, Windamere Venture Partners, and unnamed individual investors.